Title:
A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG-Naïve Non-Muscle-Invasive Bladder Cancer Patients (POTOMAC)
Phase:
III
Contact:
Gabriele Bentz / Kontaktperson
Email-Address:
Gabriele.Bentz@med.uni-heidelberg.de
Clinical Investigator:
Dr. Gencay Hatiboglu
Registration:
Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe
NCT03528694
EudraCT-Number:
(siehe EU klinisches Studienregister)
2017-002979-26